Results 51 to 60 of about 15,932 (195)

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods

ESC Heart Failure, 2023
Aims Head‐to‐head comparisons among SGLT2 inhibitors treatments in established heart failure remain absent. We conducted a systematic review of dedicated heart failure trials to assess indirectly the composite outcomes and individual clinical endpoints ...
Hai‐Bin Chen, Yao‐Lin Yang, Rong‐Sen Meng, Xue‐Wei Liu   +3 more
doaj   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

IMPACT OF DAPAGLIFLOZIN ON APOPTOSIS AND EFFECTOR CYTOTOXIC CELLS USING BREAST CANCER CELLS IN MICE [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University
Background: Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor with anti-inflammatory, antioxidant, and apoptosis modulator activity.
Shimaa M. Elkhyat, Nageh Elmahdy, Mayada Elhusseiny, Abdel aziz Zidan   +3 more
doaj   +1 more source

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

BMC Medicine, 2022
Background Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic
Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyun-Ju Lee, Ro-kyung Moon, Yong-Joon Lee, Seung-Jun Lee, Oh-Hyun Lee, Choongki Kim, Jaewon Oh, Chan Joo Lee, Yong-ho Lee, Seil Park, Ok-Hee Jeon, Donghoon Choi, Geu-Ru Hong, Jung-Sun Kim   +16 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan

Kidney International Reports
Introduction: Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney disease (ADPKD) has not been established ...
Kiyotaka Uchiyama, Daisuke Kamano, Tomoki Nagasaka, Eriko Yoshida Hama, Ryoichi Shirai, Rena Sumura, Ei Kusahana, Akane Yanai, Takashin Nakayama, Takahide Kimura, Rina Takahashi, Takahiro Kasai, Takaya Tajima, Koji Hosoya, Tatsuhiko Azegami, Shintaro Yamaguchi, Jun Yoshino, Jun Ito, Matsuhiko Hayashi, Takeshi Kanda, Yoshitaka Ishibashi, Naoki Washida, Hiroshi Itoh, Kaori Hayashi   +23 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes

Diabetology & Metabolic Syndrome, 2023
Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduced the risk of cardiovascular and renal outcomes in patients with type 2 diabetes (T2D), but the underlying mechanism has not been well elucidated.
Jia Liu, Xiaona Chang, Xiaoyu Ding, Xueqing He, Jiaxuan Wang, Guang Wang   +5 more
doaj   +1 more source